Primary Sclerosing Cholangitis (PSC): A Patient's Guide

Primary sclerosing cholangitis (PSC) is a chronic, progressive liver disease in which your immune system attacks the large bile ducts — both inside and outside the liver — causing inflammation, scarring, and narrowing (strictures) that block bile flow. Unlike PBC (which targets small intrahepatic ducts and has effective treatment with UDCA), PSC targets the larger ducts, has no proven drug therapy, and carries a unique and serious complication profile — including a significantly elevated risk of bile duct cancer (cholangiocarcinoma).

PSC predominantly affects men (2:1 male-to-female ratio) and is strongly associated with inflammatory bowel disease (IBD) — approximately 70–80% of PSC patients have ulcerative colitis or Crohn's disease. The median age at diagnosis is 30–40 years. It's relatively rare (affecting approximately 6–16 per 100,000 people), but for those who have it, PSC is one of the most challenging liver diseases to manage — because of the absence of proven medical therapy, the unpredictable course, and the cancer risk that hangs over every surveillance visit.

What's happening to your bile ducts

Your bile ducts form a branching network — from tiny ducts inside the liver to larger ducts that merge into the common bile duct, which carries bile to the intestines. In PSC, immune-mediated inflammation targets these ducts — particularly the medium and large ducts — causing progressive scarring that narrows the ducts (strictures). As strictures develop, bile flow becomes obstructed (cholestasis), leading to bile backing up in the liver, progressive liver inflammation and fibrosis from retained bile acids, and episodes of bacterial cholangitis (infection in blocked bile ducts — causing fever, pain, and jaundice).

The characteristic imaging finding is a "beaded" appearance of the bile ducts on MRCP (MR cholangiopancreatography) or ERCP (endoscopic retrograde cholangiopancreatography) — alternating areas of narrowing (strictures) and dilation, giving the ducts an irregular, segmented appearance.

How PSC is diagnosed

MRCP (MR cholangiopancreatography) is the primary diagnostic tool — a non-invasive MRI technique that visualizes the bile ducts without the need for contrast injection or endoscopy. The characteristic multifocal strictures and dilations on MRCP, combined with elevated ALP (alkaline phosphatase) and the appropriate clinical context (young male with IBD), is usually sufficient for diagnosis.

ERCP is reserved for therapeutic interventions (dilating dominant strictures, placing stents) rather than diagnosis — because it carries procedural risks (pancreatitis, infection).

Liver biopsy may be needed to diagnose small-duct PSC (where the large ducts appear normal on imaging but histology shows characteristic duct inflammation) or to stage fibrosis.

Key lab findings: Elevated ALP and GGT (often 2–10x normal). ALT and AST may be mildly elevated or normal. AMA (anti-mitochondrial antibody) is typically negative — distinguishing PSC from PBC. p-ANCA (perinuclear antineutrophil cytoplasmic antibody) is positive in approximately 60–80% of PSC patients — supportive but not diagnostic.

The PSC-IBD connection

The relationship between PSC and inflammatory bowel disease is one of the most important in hepatology — and one of the most poorly understood:

• 70–80% of PSC patients have IBD (predominantly ulcerative colitis, but Crohn's colitis also occurs)

• The IBD in PSC patients often has distinct features — more extensive colonic involvement, milder symptoms, but paradoxically higher colorectal cancer risk

• The severity of IBD does NOT correlate with PSC severity — you can have mild IBD and severe PSC, or vice versa

• Colectomy (removal of the colon) for IBD does NOT prevent PSC progression — the liver disease runs its own course

• PSC can be diagnosed before, simultaneously with, or after IBD — sometimes by decades

Critical screening implication: All PSC patients need colonoscopy screening — even those without IBD symptoms — because subclinical IBD may be present. If IBD is confirmed, annual colonoscopy with surveillance biopsies is recommended due to the elevated colorectal cancer risk (which is higher in PSC-IBD than in IBD alone).

Treatment: the frustrating reality

PSC is the only major autoimmune liver disease with no proven drug therapy. This is the hardest aspect of PSC for patients and doctors alike.

What doesn't work (despite widespread use)

UDCA (ursodeoxycholic acid): Despite being the cornerstone of PBC treatment, UDCA has not been convincingly shown to improve transplant-free survival in PSC. High-dose UDCA (28–30 mg/kg/day) actually showed worse outcomes in a large trial. Standard-dose UDCA (13–15 mg/kg/day) may improve liver biochemistry (ALP decreases) but hasn't demonstrated survival benefit. The AASLD does NOT recommend UDCA as standard treatment for PSC. However, some hepatologists still prescribe it at standard doses, particularly for patients with biochemical improvement — this remains debated.

What's being investigated

Nor-UDCA (norursodeoxycholic acid) — a modified bile acid showing promise in Phase 2/3 trials. Obeticholic acid (OCA) and other FXR agonists. PPAR agonists (bezafibrate, seladelpar). Vancomycin (particularly in pediatric PSC — some encouraging case series). Vedolizumab (gut-selective immunosuppressant — being studied for PSC given the IBD connection). The PSC treatment pipeline is active — but nothing is yet approved or proven.

What IS done

Dominant stricture management: Dominant strictures (severe narrowings in the common bile duct or major hepatic ducts causing significant bile flow obstruction) are treated endoscopically — ERCP with balloon dilation ± short-term stent placement to relieve the obstruction. This doesn't treat the underlying disease but relieves symptoms (jaundice, itching, cholangitis) and may improve biochemistry.

Cholangitis treatment: Bacterial cholangitis (fever + jaundice + right upper quadrant pain = Charcot's triad) requires prompt antibiotics and often ERCP to drain infected bile. Recurrent cholangitis accelerates liver damage and is an indication for transplant discussion.

Pruritus management: The same treatment ladder as PBC — cholestyramine → rifampin → naltrexone → sertraline. Full itching guide here.

IBD management: Coordinated with gastroenterology. The IBD treatment doesn't change PSC outcomes, but controlling intestinal inflammation is important for overall health and colorectal cancer prevention.

The cancer risk: cholangiocarcinoma

This is what makes PSC uniquely dangerous among autoimmune liver diseases. PSC patients have a lifetime risk of cholangiocarcinoma (bile duct cancer) of approximately 10–15% — with an annual incidence of 0.5–1.5% per year. Cholangiocarcinoma can develop at any stage of PSC — not just in cirrhosis — and is notoriously difficult to detect early because it grows within the bile ducts and can mimic PSC strictures on imaging.

Surveillance: Annual MRCP with CA 19-9 blood test is the standard approach — though sensitivity for early cholangiocarcinoma is imperfect. Any new dominant stricture, rapidly worsening jaundice, or significantly rising CA 19-9 warrants further investigation (ERCP with brush cytology, advanced imaging). The diagnosis of cholangiocarcinoma in PSC often requires tissue sampling — which is technically challenging and sometimes inconclusive.

PSC patients also have elevated risk of gallbladder cancer (gallbladder polyps in PSC patients warrant cholecystectomy if >8 mm), hepatocellular carcinoma (if cirrhosis is present — standard HCC screening applies), and colorectal cancer (if IBD is present — annual colonoscopy with biopsies).

Liver transplant for PSC

PSC is one of the leading indications for liver transplant — accounting for approximately 5–10% of all liver transplants in the US and a higher proportion in Northern Europe. Transplant is indicated for decompensated cirrhosis (ascites, HE, variceal bleeding unresponsive to management), recurrent cholangitis despite endoscopic management, intractable pruritus not responsive to medical therapy, and cholangiocarcinoma within specific protocols (select patients with early-stage hilar cholangiocarcinoma may qualify for transplant after neoadjuvant chemoradiation — outcomes at experienced centers are good).

Post-transplant outcomes for PSC are excellent — 5-year survival exceeds 80%. However, PSC can recur in the transplanted liver in approximately 20–25% of patients — usually within 5–10 years. Recurrent PSC is typically milder than the original disease and progresses slowly, but it requires ongoing monitoring.

Monitoring and tracking

Because PSC lacks effective drug therapy, monitoring IS the management strategy — detecting complications early and intervening when they arise:

• Liver function tests every 3–6 months. ALP trend is the primary biochemical marker.

• MRCP annually for cholangiocarcinoma surveillance + CA 19-9 blood test.

• Annual colonoscopy with biopsies if IBD is present (colorectal cancer surveillance).

• FibroScan periodically to assess fibrosis progression.

• HCC screening if cirrhosis is established.

• Variceal screening if cirrhosis is established.

• DEXA scan for bone density (cholestatic diseases have high osteoporosis rates).

Upload every lab report to LiverTracker. Your ALP trend, bilirubin, albumin, and all other values are tracked on visual trend charts. Log MRCP and colonoscopy results in the imaging tracker. Share your complete record with both your hepatologist and gastroenterologist.

Frequently asked questions

Is PSC the same as PBC?

No. PSC affects large bile ducts, predominantly affects men, is strongly associated with IBD, has no proven drug therapy, and carries cholangiocarcinoma risk. PBC affects small bile ducts, predominantly affects women, is not associated with IBD, responds well to UDCA, and has lower cancer risk (only in cirrhotic stage). They're both autoimmune cholestatic diseases — but that's where the similarity ends.

Will UDCA help my PSC?

It may improve your ALP level, but it hasn't been shown to improve long-term outcomes (transplant-free survival) in PSC. High-dose UDCA may actually be harmful. Some hepatologists prescribe standard-dose UDCA and monitor for biochemical response — others don't prescribe it at all. This is a discussion to have with your hepatologist based on your specific situation and values.

How fast does PSC progress?

Highly variable — the median time from diagnosis to transplant or death is approximately 12–15 years, but some patients progress rapidly (within 5 years) while others remain stable for 20+ years. There are no reliable predictors of rapid progression, which makes the uncertainty particularly difficult to manage psychologically. Managing fear of progression is an important part of living with PSC.

Do I need a colonoscopy even if I don't have IBD symptoms?

Yes — because subclinical IBD (present without obvious symptoms) is common in PSC, and the colorectal cancer risk in PSC-IBD is higher than in IBD alone. If initial colonoscopy confirms IBD, annual surveillance colonoscopy with biopsies is recommended. If initial colonoscopy is normal, repeat every 3–5 years to screen for new-onset IBD.

Can PSC come back after transplant?

Yes — recurrent PSC occurs in approximately 20–25% of transplant recipients, usually within 5–10 years. It's typically milder and slower-progressing than the original disease. The mechanism of recurrence is not fully understood — which complicates the already-frustrating absence of effective medical therapy. Post-transplant monitoring for recurrence is part of lifelong follow-up.

PSC is the liver disease without a drug — and that's an honest, frustrating reality. But monitoring catches complications early, endoscopic intervention manages strictures, transplant offers excellent outcomes when needed, and the research pipeline is the most active it's ever been. Track everything. Stay vigilant. And know that the absence of treatment today doesn't mean the absence of treatment tomorrow.

→ Check Your Liver Enzymes Free

→ Start Tracking Free

→ Log Your Screenings

Medical Disclaimer: This article is for informational and educational purposes only. PSC management should be directed by a hepatologist experienced in cholestatic liver disease. Never change treatment without medical guidance. Visit livertracker.com/medical-disclaimer.